Rocket Pharmaceuticals
RCKT
163 hedge funds and large institutions have $1.34B invested in Rocket Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 71 increasing their positions, 37 reducing their positions, and 17 closing their positions.
473% more call options, than puts
Call options by funds: $3.81M | Put options by funds: $664K
92% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 37
3.68% more ownership
Funds ownership: 94.95% → 98.63% (+3.7%)
6% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 17
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
2% less funds holding
Funds holding: 167 → 163 (-4)
8% less capital invested
Capital invested by funds: $1.46B → $1.34B (-$123M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MC
Maverick Capital
Dallas,
Texas
|
+$19.8M |
| 2 |
Goldman Sachs
New York
|
+$12.2M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$12.1M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$11.8M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$8.37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$25M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$11.2M |
| 3 |
Nuveen
Charlotte,
North Carolina
|
-$6.86M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$5.54M |
| 5 |
TM
Tiger Management
New York
|
-$5.47M |
RCKT Hedge Fund Activity: Q1 2023 in Review
163 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q1 2023, worth a combined $1.34B — down 8.4% from $1.46B a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new RCKT positions and 17 closed out — a net gain of 1 holder — while 71 added to existing stakes and 37 trimmed.
The largest buyer was Maverick Capital, adding an estimated $19.8M. The largest seller was RA Capital Management, cutting an estimated $25M.
- 163 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q1 2023, down from 167 in Q4 2022.
- Funds reported $1.34B of Rocket Pharmaceuticals stock for Q1 2023, down 8.4% quarter-over-quarter.
- 18 funds opened new Rocket Pharmaceuticals positions in Q1 2023 and 17 closed out, a net change of +1 holder.
- The largest Rocket Pharmaceuticals buyer in Q1 2023 was Maverick Capital, an estimated $19.8M added.
- The largest Rocket Pharmaceuticals seller in Q1 2023 was RA Capital Management, an estimated $25M sold.
Based on aggregated 13F filings for Q1 2023.